VFY — Vitrafy Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- AU$215.61m
- AU$189.81m
- AU$0.17m
Annual balance sheet for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.963 | 1.72 | 6.41 | 19.5 | 26.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.97 | 2.18 | 2.24 | 1.66 | 1.2 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.49 | 3.9 | 9.03 | 31.3 | 42.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.879 | 1.03 | 0.746 | 0.593 | 0.837 |
| Total Assets | 4.37 | 4.93 | 9.78 | 31.8 | 43.2 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.3 | 19 | 33.9 | 2.72 | 1.78 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11.6 | 19.6 | 34.4 | 3.08 | 2.1 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -7.27 | -14.6 | -24.6 | 28.8 | 41.1 |
| Total Liabilities & Shareholders' Equity | 4.37 | 4.93 | 9.78 | 31.8 | 43.2 |
| Total Common Shares Outstanding |